Inovio Biomedical’s First Proprietary DNA Vaccine Achieves 100% Protection Against Avian Flu In Pre-Clinical Testing
By Content Keyword RSS on Jul 25, 2008 in Health, Main Content
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using a proprietary electroporation-based DNA delivery platform, announced recently pre-clinical results from two proprietary plasmid DNA-based universal influenza vaccine candidates using the company’s proprietary electroporation delivery technology and, specifically, a new intradermal device. In this study, 100% of the immunized mice given a lethal challenge of highly pathogenic H5N1 influenza virus